Keytruda (pembrolizumab) is used to treat solid tumors with a biomarker referred to as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Includes Keytruda side effects, interactions and indications.
Selected KEYTRUDA® (pembrolizumab) Indications in the U.S. Urothelial Cancer KEYTRUDA, in combination with enfortumab vedotin, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial canc...
To date, more than 1600 trials are evaluating Keytruda across a range of cancer types and treatment settings. Keytruda has approved indications in melanoma; non-small cell lung cancer; head and neck squamous cell cancer; classical Hodgkin lymphoma; primary mediastinal large B-cell lymphoma; urotheli...
Aetna considers all other indications as experimental, investigational, or unproven. Continuation of Therapy Aetna considers continuation of pembrolizumab (Keytruda) therapy medically necessary for the following indications: Adjuvant treatment of melanoma, adjuvant high-risk early-stage TNBC, RCC, or NSCLC ...
The FDA has set a Prescription Drug User Fee Act, or target action, date of January 20, 2024. The results are also being discussed with regulatory authorities worldwide. In the U.S., KEYTRUDA has two approved indica...
Merck has a comprehensive clinical development program in endometrial cancer. In the U.S., KEYTRUDA has two approved indications in endometrial cancer: in combination with LENVIMA® (lenvatinib), for the treatment of patients with advanc...
this first Phase 1 clinical study are to establish the safety and tolerability profile of PRT3789 as both monotherapy and in combination with docetaxel, evaluate activity, pharmacokinetics and pharmacodynamics and determine a dose and potential indications for advancement into a registrational ...
(NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the topline clinical data from the final analysis of the Phase 1/2 clinical trial of galin...
Selected KEYTRUDA® (pembrolizumab) Indications in the U.S. Urothelial Carcinoma KEYTRUDA, in combination with enfortumab vedotin, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy...
Selected KEYTRUDA® (pembrolizumab) Indications in the U.S. Non-Small Cell Lung Cancer KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients ...